Please login to the form below

Eloctate

This page shows the latest Eloctate news and features for those working in and with pharma, biotech and healthcare.

well as Biogen’s Eloctate, Bayer’s Kovaltry and CSLBehring’s Afstyla.

Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ

Bioverativ separated from Biogen last year to create a stand-alone haemophilia specialist with two marketed drugs - Eloctate (efmoroctocog alfa) and Alprolix (eftrenonacog alfa) which brought in sales estimated to be ... longer acting therapies such as
New data could unlock bigger market for Roche’s Hemlibra

Haemophilia A treatment is being transformed by a series of long-acting Factor VIII products such as Biogen’s Eloctate, Shire’s Adynovate, Bayer’s Kovaltry and CSLBehring’s Afstyla, which
Biogen spin-out makes first acquisition

Eloctate (efmoroctocog alfa) and Aprolix (eftrenonacog alfa).
Biogen completes haemophilia business separation

haemophilia A and B drugs, Eloctate (efmoroctocog alfa) and Aprolix (eftrenonacog alfa). ... The biotech was a latecomer to the $10bn haemophilia sector, but quickly gained ground with long-acting, low-dose therapies Eloctate and Aprolix, which
Sobi looks to real-world trial to push Elocta take-up

It took over EU commercialisation rights from partner Biogen – which sells the drug as Eloctate in the US - last March.

More from news
Approximately 3 fully matching, plus 20 partially matching documents found.

Deal Watch January 2018

Paying $105 per share in cash (64% premium over Bioverativ’s closing price on 19 January), Sanofi gains the marketed products, Eloctate (haemophilia A therapy) and Alprolix (haemophilia B therapy), as ... During 2016 Eloctate and Alprolix generated

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Home based, Editorial Team Leader, Medical Communications: Excellent package

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Home based, Senior Medical Writer, Medical Communications: Excellent package

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Home based, Principal Medical Writer, Medical Communications: Excellent package

Add my company

Founded in 2002, Cactus Communications is a fully integrated, global scholarly communications company with offices in Japan, South Korea, India,...

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....